{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:06:44Z","timestamp":1762459604583,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"am","delay-in-days":294,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000980","name":"Arthritis Foundation","doi-asserted-by":"publisher","award":["5906"],"award-info":[{"award-number":["5906"]}],"id":[{"id":"10.13039\/100000980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007104","name":"Training Program","doi-asserted-by":"publisher","award":["2T32AR050942-06A1"],"award-info":[{"award-number":["2T32AR050942-06A1"]}],"id":[{"id":"10.13039\/100007104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AR061297"],"award-info":[{"award-number":["R01AR061297"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R21AR062765"],"award-info":[{"award-number":["1R21AR062765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clim.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T19:12:50Z","timestamp":1529435570000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor"],"prefix":"10.1016","volume":"194","author":[{"given":"Yujuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloni","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Ilstad-Minnihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sashi","family":"Ayyangar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle D.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman T.","family":"Ilowite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Macaubas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Mellins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2018.06.005_bb0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2018.06.005_bb0010","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"15970","article-title":"HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis","volume":"112","author":"Ombrello","year":"2015"},{"key":"10.1016\/j.clim.2018.06.005_bb0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.0906-6705.2005.00271.x","article-title":"Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis","volume":"14","author":"Frosch","year":"2005","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.clim.2018.06.005_bb0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2018.06.005_bb0025","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.22644","article-title":"Specific gene expression profiles in systemic juvenile idiopathic arthritis","volume":"56","author":"Ogilvie","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.06.005_bb0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clim.2011.12.008","article-title":"Alternative activation in systemic juvenile idiopathic arthritis monocytes","volume":"142","author":"Macaubas","year":"2012","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clim.2009.09.010","article-title":"Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states","volume":"134","author":"Macaubas","year":"2010","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0040","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/art.22981","article-title":"Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome","volume":"56","author":"Fall","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.06.005_bb0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molimm.2014.02.011","article-title":"Serum amyloid a induces mitogenic signals in regulatory T cells via monocyte activation","volume":"59","author":"Nguyen","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun."},{"key":"10.1016\/j.clim.2018.06.005_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ncprheum0084","article-title":"Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome","volume":"2","author":"Woo","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.clim.2018.06.005_bb0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.12688\/f1000research.11327.1","article-title":"New frontiers in the treatment of systemic juvenile idiopathic arthritis","volume":"6","author":"Canny","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.clim.2018.06.005_bb0065","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMe1212640","article-title":"A new era in the treatment of systemic juvenile idiopathic arthritis","volume":"367","author":"Sandborg","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.06.005_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"7","author":"Giancane","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clim.2018.06.005_bb0075","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2018.06.005_bb0080","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2018.06.005_bb0085","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2018.06.005_bb0090","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.06.005_bb0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.06.005_bb0100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0105","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00296-011-2249-4","article-title":"Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)","volume":"32","author":"Hedrich","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"2000","key":"10.1016\/j.clim.2018.06.005_bb0110","first-page":"6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"1950","journal-title":"J. Immunol. (Baltimore, MD)"},{"key":"10.1016\/j.clim.2018.06.005_bb0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.clim.2018.06.005_bb0120","series-title":"F1000prime Reports","first-page":"13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Martinez","year":"2014"},{"key":"10.1016\/j.clim.2018.06.005_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.06.005_bb0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","article-title":"Alternative activation of macrophages: mechanism and functions","volume":"32","author":"Gordon","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.06.005_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2015.12.011","article-title":"Altered signaling in systemic juvenile idiopathic arthritis monocytes","volume":"163","author":"Macaubas","year":"2016","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0140","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Sci. (New York, N.Y.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0150","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2014.05.005","article-title":"Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis","volume":"26","author":"Avau","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.clim.2018.06.005_bb0160","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2018.06.005_bb0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2017.00123","article-title":"The P2X7 receptor-Interleukin-1 liaison","volume":"8","author":"Giuliani","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.clim.2018.06.005_bb0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0076-6879(04)84010-2","article-title":"Mixed-model regression analysis and dealing with interindividual differences","volume":"384","author":"Van Dongen","year":"2004","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.clim.2018.06.005_bb0175","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.athoracsur.2015.11.024","article-title":"Adjust for multiple comparisons? It's not that simple","volume":"101","author":"Althouse","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.clim.2018.06.005_bb0180","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/0140-6736(91)92725-H","article-title":"Production of interleukin-1-receptor antagonist during experimental endotoxaemia","volume":"338","author":"Granowitz","year":"1991","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clim.2018.06.005_bb0185","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1084\/jem.20050640","article-title":"Blocking IL-1 in systemic inflammation","volume":"201","author":"Dinarello","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2018.06.005_bb0190","first-page":"779","article-title":"Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis","volume":"13","author":"De Benedetti","year":"1995","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2018.06.005_bb0195","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.clim.2010.04.009","article-title":"Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes","volume":"136","author":"Sanda","year":"2010","journal-title":"Clin. Immunol. (Orlando, Fla.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2018.06.005_bb0210","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clim.2018.06.005_bb0215","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2598::AID-IMMU2598>3.0.CO;2-K","article-title":"IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes","volume":"28","author":"Hurme","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-016-1212-x","article-title":"Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy","volume":"19","author":"Brachat","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2018.06.005_bb0225","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.clim.2018.06.005_bb0230","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.clim.2018.06.005_bb0235","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1073\/pnas.0402800101","article-title":"Differences in signaling pathways by IL-1beta and IL-18","volume":"101","author":"Lee","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2018.06.005_bb0240","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4049\/jimmunol.139.6.1902","article-title":"Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro","volume":"139","author":"Dinarello","year":"1987","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.clim.2018.06.005_bb0245","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/eji.1830190207","article-title":"Autoregulation of interleukin 1 production","volume":"19","author":"Manson","year":"1989","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0250","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1038\/ncomms10555","article-title":"Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1beta secretion in response to ATP","volume":"7","author":"Karmakar","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2018.06.005_bb0255","doi-asserted-by":"crossref","first-page":"245804","DOI":"10.1155\/2013\/245804","article-title":"IRF5 is a specific marker of inflammatory macrophages in vivo","volume":"2013","author":"Weiss","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.clim.2018.06.005_bb0260","doi-asserted-by":"crossref","first-page":"549691","DOI":"10.1155\/2015\/549691","article-title":"PPARgamma and the innate immune system mediate the resolution of inflammation","volume":"2015","author":"Croasdell","year":"2015","journal-title":"PPAR Res."},{"key":"10.1016\/j.clim.2018.06.005_bb0265","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.immuni.2010.11.009","article-title":"STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells","volume":"33","author":"Szanto","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.06.005_bb0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.metabol.2006.10.007","article-title":"Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells","volume":"56","author":"Kim","year":"2007","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.clim.2018.06.005_bb0275","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/cyto.2002.1945","article-title":"Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma","volume":"18","author":"Meier","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2018.06.005_bb0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/clc.20566","article-title":"Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation","volume":"32","author":"Chen","year":"2009","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.clim.2018.06.005_bb0285","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/HJH.0b013e3283396e4e","article-title":"Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta\/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain","volume":"28","author":"Glatz","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.clim.2018.06.005_bb0290","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/eji.201040319","article-title":"IL-1: discoveries, controversies and future directions","volume":"40","author":"Dinarello","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0295","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/art.38359","article-title":"Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-gamma","volume":"66","author":"Avau","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.clim.2018.06.005_bb0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4049\/jimmunol.175.1.131","article-title":"Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction","volume":"175","author":"Hu","year":"2005","journal-title":"J. Immunol. (Baltimore, MD: 1950)"},{"key":"10.1016\/j.clim.2018.06.005_bb0305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2018.06.005_bb0310","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/10799900152434358","article-title":"IFN-gamma inhibits lipopolysaccharide-induced interleukin-1 beta in primary murine macrophages via a Stat1-dependent pathway","volume":"21","author":"De Boer","year":"2001","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.clim.2018.06.005_bb0315","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/jir.2006.26.739","article-title":"A role for Stat1 in the regulation of lipopolysaccharide-induced interleukin-1beta expression","volume":"26","author":"Joshi","year":"2006","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.clim.2018.06.005_bb0320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/ni.2474","article-title":"Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta","volume":"14","author":"Mishra","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2018.06.005_bb0325","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1189\/jlb.0905503","article-title":"IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells","volume":"79","author":"Strengell","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2018.06.005_bb0330","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2014.927759","article-title":"Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis","volume":"21","author":"Goncalves","year":"2014","journal-title":"Amyloid"},{"key":"10.1016\/j.clim.2018.06.005_bb0335","doi-asserted-by":"crossref","first-page":"19408","DOI":"10.1074\/jbc.M111302200","article-title":"Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1","volume":"277","author":"Wong","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2018.06.005_bb0340","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1093\/nar\/gkg929","article-title":"Transcription factor ZBP-89 is required for STAT1 constitutive expression","volume":"31","author":"Bai","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.clim.2018.06.005_bb0345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/gtc.12316","article-title":"Distal regulatory element of the STAT1 gene potentially mediates positive feedback control of STAT1 expression","volume":"21","author":"Yuasa","year":"2016","journal-title":"Genes Cells"},{"key":"10.1016\/j.clim.2018.06.005_bb0350","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10238-009-0083-8","article-title":"DNA methylation and not allelic variation regulates STAT6 expression in human T cells","volume":"10","author":"Kim","year":"2010","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.clim.2018.06.005_bb0355","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.clim.2018.06.005_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/art.40498","article-title":"IL1RN Variation influences both disease susceptibility and response to human recombinant IL-1RA therapy in systemic juvenile idiopathic arthritis","author":"Arthur","year":"2018","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617307386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661617307386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:57:24Z","timestamp":1761494244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661617307386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":72,"alternative-id":["S1521661617307386"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2018.06.005","relation":{},"ISSN":["1521-6616"],"issn-type":[{"type":"print","value":"1521-6616"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}